InspireMD reports Q2 EPS (26c) vs (22c) last year

Reports Q2 revenue $1.778M vs $1.739M last year. Marvin Slosman, CEO of InspireMD (NSPR), commented: “Over the last few months, our team has executed the most significant set of milestones in InspireMD’s history, as we obtained approval for our proprietary CGuard Prime carotid stent system in the U.S. and began its commercial rollout. These transformational milestones were years in the making and validate our vision and execution. Backed by a fully trained, world-class commercial team, we are now focused on scaling with discipline and precision to unlock the full potential of our platform.”